Loading organizations...
Based in Beijing, China, Deep Intelligent Pharma develops artificial intelligence and blockchain technologies to automate clinical workflows and accelerate drug discovery for the global pharmaceutical industry. The company provides a software-as-a-service platform utilizing multi-agent AI systems to manage complex clinical research tasks, medical translations, and intelligent documentation generation. To date, the enterprise has successfully served over 1,000 pharmaceutical and medtech companies across more than 40,000 projects, including securing regulatory approval for the Japanese biotechnology firm Immunorock. Deep Intelligent Pharma has raised significant capital to fund its ongoing operations, recently securing a nearly $50 million Series D financing round following a previous $15 million Series B. The organization's venture capital backers include prominent institutional investment firms such as CDH Baifu, New Ding Capital, and Sequoia China. Deep Intelligent Pharma was founded in 2017 by Li Xing.
Deep Intelligent Pharma has raised $60.0M across 1 funding round.
Deep Intelligent Pharma employs an AI-native multi-agent platform designed to transform pharmaceutical R&D and automate clinical trial workflows.
The company aims to transform pharmaceutical R&D by automating clinical trial workflows, which contributes to increased efficiency and potentially faster drug development cycles.
Yes, the company's solutions are noted for driving capital efficiency in the biotech sector, with specific mention of its impact within China's biotech landscape.
Deep Intelligent Pharma employs an AI-native multi-agent platform designed to transform pharmaceutical R&D and automate clinical trial workflows.
The company aims to transform pharmaceutical R&D by automating clinical trial workflows, which contributes to increased efficiency and potentially faster drug development cycles.
Yes, the company's solutions are noted for driving capital efficiency in the biotech sector, with specific mention of its impact within China's biotech landscape.
Deep Intelligent Pharma is a private startup operating from its headquarters in Singapore. The company is identified as an AI clinical trial company, with a strategic focus on integrating artificial intelligence to innovate and optimize processes within the pharmaceutical industry. Its core mission revolves around enhancing the efficiency and effectiveness of drug development, addressing critical challenges faced in bringing new therapies to market.
The foundation of Deep Intelligent Pharma's technological approach is its revolutionary AI-native multi-agent platform. This advanced system is specifically engineered to transform pharmaceutical research and development by introducing sophisticated AI capabilities across the entire drug discovery and development lifecycle. The platform's design emphasizes intelligent automation, predictive analytics, and data-driven insights to improve decision-making and operational execution.
A key application of this platform involves the automation of clinical trial workflows. By streamlining these inherently complex and time-consuming processes, Deep Intelligent Pharma aims to significantly reduce the operational burden, minimize human error, and accelerate the timelines typically associated with clinical research. This efficiency gain is crucial for bringing new pharmaceutical products to market more rapidly and cost-effectively.
Furthermore, Deep Intelligent Pharma positions its AI-driven solutions as a catalyst for fostering capital efficiency within the broader biotech sector. The company's technology enables biotech firms, particularly highlighted in regions such as China, to achieve substantial progress and innovation with a more optimized deployment of financial resources. This contributes to what the company describes as a "DeepSeek moment" in the industry, signifying a breakthrough in capital-efficient development and a more agile approach to drug discovery.
Deep Intelligent Pharma has raised $60.0M across 1 funding round. Most recently, it raised $60.0M Series D in February 2026.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 2, 2026 | $60M Series D | — | CDH Investments, Jinyi Capital, Kaitai Capital, Trustar Capital, XIN Ding Capital | Announced |
